CG Oncology
Developing cretostimogene for bladder cancer alongside contract fill-and-finish manufacturing.
$73.91
After-hours close−0.42 (−0.57%)
At close$74.33(−5.92%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.86 | — | — |
| Aug 2026 | −$0.66 | −$0.90 | −35.5% |
| Aug 2026 | −$0.66 | −$0.90 | −35.5% |
| May 2026 | −$0.58 | −$0.71 | −22.4% |
| Feb 2026 | −$0.61 | −$0.51 | +16.4% |
The latest year is open to everyone — the 8 quarters behind it read with an account. Sign in | |||
| Nov 2025 | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | −$0.42 | — | — |
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | −$0.67 | — | — |
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 13, 2026 | −$0.86 | — | — | $547.7K | — | — |
| Aug 7, 2026 | −$0.66 | −$0.90 | −35.5% | $360.8K | $1.2M | +220.7% |
| Aug 6, 2026 | −$0.66 | −$0.90 | −35.5% | $360.8K | $1.2M | +220.7% |
| May 8, 2026 | −$0.58 | −$0.71 | −22.4% | $453.0K | $1.1M | +139.1% |
| Feb 27, 2026 | −$0.61 | −$0.51 | +16.4% | $450.5K | $2.3M | +412.9% |
The latest year is open to everyone — the 8 quarters behind it read with an account. Sign in | ||||||
| Nov 14, 2025 | ||||||
| Aug 8, 2025 | ||||||
| May 13, 2025 | ||||||
| Mar 28, 2025 | ||||||
| Nov 14, 2024 | −$0.42 | — | — | — | — | — |
| Aug 8, 2024 | ||||||
| May 9, 2024 | ||||||
| Mar 26, 2024 | −$0.67 | — | — | — | — | — |